Group 1 - The CRO sector is under pressure, with notable declines in stock prices: Kanglong Chemical down 4.32% to HKD 21.24, Zhaoyan New Drug down 3.29% to HKD 21.16, Kylin Pharmaceutical down 2.31% to HKD 78.15, and Weiya Bio down 1.98% to HKD 1.98 [1][1][1] - The revised U.S. Biodefense Law, part of the 2026 National Defense Authorization Act (NDAA), has passed the Senate with a vote of 77 to 20 and is expected to be signed by the President, completing the legislative process [1][1][1] - According to Cinda Securities, the Biodefense Law has been a significant factor in suppressing the valuation of the CXO sector over the past two years, but the final version is relatively moderate compared to the initial draft, as it does not specifically name companies [1][1][1] Group 2 - With the Federal Reserve entering a rate-cutting cycle, global biopharmaceutical investment and financing are expected to improve marginally [1][1][1] - The implementation of the Biodefense Law is anticipated to lead to a dual recovery in both performance and valuation for the CXO sector [1][1][1]

Group 1 - CRO concept stocks are under pressure, with notable declines in share prices: Kanglong Chemical down 4.32% to HKD 21.24, Zhaoyan New Drug down 3.29% to HKD 21.16, Kelaiying down 2.31% to HKD 78.15, and Weiya Bio down 1.98% to HKD 1.98 [1] - The revised U.S. Biodefense Law was passed in the Senate with a vote of 77 in favor and 20 against, completing the main legislative process and is set to be signed by the President [1] - According to Xinda Securities, the Biodefense Law has been a significant factor suppressing the valuation of the CXO sector over the past two years, but the final version is relatively mild compared to the initial draft, as it does not name specific companies [1] Group 2 - With the Federal Reserve entering a rate-cutting phase, global biopharmaceutical investment and financing are expected to improve marginally [1] - The implementation of the Biodefense Law is anticipated to lead to a dual recovery in performance and valuation for the CXO sector [1]

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The biopharmaceutical investment and financing environment has shown significant recovery since the second half of 2025, with a total financing amount of USD 30.32 billion from July to November 2025, representing a year-on-year increase of 30.90% [4] - The number of new drug IND applications stabilized in 2025, with approximately 1,897 applications from January to November, reflecting a year-on-year growth of about 7.91% [4] - The demand for CRO services has shown a clear turning point, and the report continues to recommend opportunities in the innovative drug industry chain (CXO + research services) for 2026 [4] Summary by Sections Industry Performance - The biopharmaceutical sector experienced a decline of 0.14% in the third week of December 2025, outperforming the CSI 300 index by 0.14 percentage points, ranking 22nd among 31 sub-industries [7][14] - The offline pharmacy sector saw the highest increase, rising by 5.59%, while the chemical preparation sector had the largest decline at 2.1% [18][22] Investment Opportunities - The report highlights the strong performance of leading CXO and research service companies, with many exceeding earnings expectations. Companies like WuXi AppTec and Tigermed have raised their earnings guidance for 2025 [5] - The report recommends a valuation switch opportunity for leading CXO and research service companies, given the continuous improvement in demand [5] Clinical Research Organizations (CRO) - There has been a notable improvement in orders for preclinical and clinical CROs, with expectations for significant improvements in financial statements for 2026 [6] - The report anticipates that the market demand will continue to focus on leading companies as the capacity of clinical CROs is expected to be streamlined [6] Monthly and Weekly Recommendations - The report recommends a monthly investment portfolio including companies such as Sanofi, Innovent Biologics, and others, focusing on innovative drug opportunities and valuation switch [8]

Group 1 - The top three companies with the highest short positions are Vanke Enterprises (02202), COSCO Shipping Holdings (01919), and Heng Rui Medicine (01276), with short ratios of 19.04%, 17.09%, and 15.18% respectively [1][2] - The companies with the largest absolute increase in short positions are Zhaoyan New Drug (06127), Lens Technology (06613), and China Everbright Holdings (00165), with increases of 2.08%, 1.68%, and 1.46% respectively [1][2] - The companies with the largest absolute decrease in short positions are ZTE Corporation (00763), Nuo Cheng Jian Hua (09969), and Yi Mai Tong (02192), with decreases of -3.12%, -2.21%, and -1.70% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include Vanke Enterprises (02202) at 19.04%, COSCO Shipping Holdings (01919) at 17.09%, and Heng Rui Medicine (01276) at 15.18% [2] - The companies with the most significant increase in short ratios include Zhaoyan New Drug (06127) from 3.50% to 5.57%, Lens Technology (06613) from 3.07% to 4.75%, and China Everbright Holdings (00165) from 2.04% to 3.51% [2] - The companies with the most significant decrease in short ratios include ZTE Corporation (00763) from 17.63% to 14.51%, Nuo Cheng Jian Hua (09969) from 5.19% to 2.97%, and Yi Mai Tong (02192) from 3.06% to 1.36% [2][3]

Core Viewpoint - Zhaoyan New Drug's stock price has shown significant volatility, with a year-to-date increase of 110.72%, but a recent decline in the last 60 days by 12.90% [1] Group 1: Stock Performance - As of December 19, Zhaoyan New Drug's stock price was 34.98 CNY per share, with a market capitalization of 26.217 billion CNY [1] - The stock has experienced a net inflow of 6.0604 million CNY from major funds, with large orders accounting for 22.37% of purchases and 20.10% of sales [1] - The stock has been on the "龙虎榜" three times this year, with the most recent occurrence on September 15 [1] Group 2: Financial Performance - For the period from January to September 2025, Zhaoyan New Drug reported a revenue of 985 million CNY, a year-on-year decrease of 26.23%, while net profit attributable to shareholders increased by 214.79% to 80.7061 million CNY [2] - The company's main business revenue composition includes 95.59% from non-clinical research services, 4.34% from clinical services, and 0.07% from experimental model supply [1] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 57.61% to 96,500, with an average of 0 shares per shareholder [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Huabao Zhongzheng Medical ETF and new entries from Guangfa Small Cap Growth Mixed Fund [3]

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2][3] Group 1: Increased Holdings - Lion Group (02562) saw the largest increase in ownership percentage, rising by 2.82% to a total of 38.88% [2] - Haotian International Construction Investment (01341) increased by 2.00%, reaching 63.13% [2] - Hongye Futures (03678) experienced a 1.47% increase, with a new holding percentage of 62.95% [2] - Red Star Macalline (01528) had a notable increase of 7.04% over the last five trading days, bringing its total to 52.61% [3] - The top ten companies with the largest increases in holdings over the last 20 days included Jihong Co. (02603) with a 20.71% increase, reaching 54.88% [4] Group 2: Decreased Holdings - Zhaoyan New Drug (06127) had the largest decrease in ownership percentage, dropping by 1.06% to 56.43% [2] - Yimai Sunshine (02522) decreased by 0.56%, now at 45.42% [2] - Southern Hong Kong American Technology (03442) saw a reduction of 0.55%, with a new holding percentage of 27.74% [2] - Over the last five trading days, Changfei Optical Fiber (06869) experienced a significant decrease of 7.35%, now at 51.47% [3] - The top ten companies with the largest decreases in holdings over the last 20 days included Shandong Molong (00568) with a 6.81% decrease, now at 51.24% [4]

Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases for companies like 招商恆生科技 (China Merchants Hengsheng Technology), 昭衍新药 (Zhaoyan Pharmaceutical), and 红星美凯龙 (Red Star Macalline) [1][2] - Conversely, companies such as 赤峰黄金 (Chifeng Jilong Gold Mining), 第一拖拉机股份 (First Tractor Company), and 国富氢能 (Guofu Hydrogen Energy) experienced the largest decreases in holdings [1][2] Summary by Category Increase in Holdings - 招商恆生科技 (03423) saw an increase of 2.80%, bringing its latest holding ratio to 5.17% [2] - 昭衍新药 (06127) increased by 2.18%, with a current holding ratio of 57.49% [2] - 红星美凯龙 (01528) rose by 1.01%, now holding 51.58% [2] - Over the last five trading days, 红星美凯龙 (01528) had the highest increase at 7.49%, with a holding ratio of 51.58% [3] - 招商恆生科技 (03423) and 昭衍新药 (06127) also saw significant increases of 3.76% and 3.57%, respectively [3] Decrease in Holdings - 赤峰黄金 (06693) experienced the largest decrease of -2.62%, with a holding ratio of 45.12% [2] - 第一拖拉机股份 (00038) decreased by -1.05%, now at 53.39% [2] - 国富氢能 (02582) saw a reduction of -0.90%, with a holding ratio of 19.12% [2] - Over the last five trading days, 招商证券 (06099) had the largest decrease at -4.28%, with a holding ratio of 23.96% [3] Long-term Trends - Over the past 20 days, 吉宏股份 (Jihong Co., Ltd.) had the highest increase at +20.90%, with a holding ratio of 54.71% [4] - The report also notes that 山东墨龙 (Shandong Molong Petroleum Machinery) had the largest decrease at -7.96%, with a holding ratio of 51.70% [4]

Group 1 - The company, Zhaoyan New Drug (603127), confirmed its capability to undertake relevant projects due to its OECD GLP certification [1]

Group 1 - The Hang Seng Index rose by 0.22%, gaining 55 points to reach 25,291 points, while the Hang Seng Tech Index increased by 0.02% with a trading volume of 84.8 billion HKD in the morning session [1] - Yichun City announced the cancellation of 27 mining rights, leading to a surge in lithium stocks, with Ganfeng Lithium rising over 6% and Tianqi Lithium increasing by over 5% [1] - Airlines showed strong performance in November's off-peak season, with Southern Airlines up over 7%, Eastern Airlines up over 5%, and Air China rising by 5% [1] Group 2 - Jiangxi International Resources saw a 6% increase as tungsten prices accelerated, reaching a historical high for tungsten concentrate [1] - Junda Co., Ltd. rose over 6% after its Chuzhou base achieved large-scale production of TOPCon batteries [1] - Changfei Optical Fiber and Cable increased by nearly 11% driven by AI computing power demand [2] Group 3 - Yaojie Ankang-B surged by 18% after announcing positive clinical results for Tiengatin in a sub-journal of The Lancet [3] - Li Ning rose by 4% with the launch of new Dragon Store and Honor Gold Standard product series, expected to create strong synergy [4] - Zhongjiao Holdings increased by 6% as its adjusted annual EBITDA exceeded expectations, with institutions focusing on subsequent classification registration progress [5] Group 4 - Tanwan rose over 4%, accumulating over 30% growth this month, partnering with COEXIST to expand its trendy toy industry layout [6] - Zhaoyan Pharmaceutical increased by over 10% as the price of experimental monkeys rose, with institutions expecting a tight supply-demand situation to persist [7] - Yidu International fell over 12% in the morning session, giving back most of its gains for the month, as Muxi Co., Ltd. listed on the Sci-Tech Innovation Board today [8]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Zhaoyan New Drug (6127.HK), which increased nearly 10% to HKD 22.48, marking a two-month high, with a cumulative increase of over 30% in December, leading to a total market capitalization of HKD 16.86 billion [1] - The price of experimental monkeys has surged, with the cost of 3-5 year old crab-eating macaques reaching HKD 140,000 each, indicating a supply-demand imbalance this year [1] - The recovery in the CRO (Contract Research Organization) industry and the upward cycle of innovative drugs are contributing factors to the rising prices of experimental monkeys, with several CRO companies, including Zhaoyan New Drug and Yinos, having substantial resources in this area [1] Group 2 - According to Founder Securities, leading CROs with rich strategic resource reserves are expected to benefit from the industry recovery and the fair value gains from monkey prices [1] - For Zhaoyan New Drug, assuming an average price of HKD 84,900 per monkey in 2024 and an increase to HKD 140,000 by Q4 2025, with an estimated output rate of 17% from 23,200 monkeys, the projected new fair value in 2025 could be approximately HKD 220 million [1]